US20110243851A1 - Glucose-peg conjugates for reducing glucose transport into a cell - Google Patents

Glucose-peg conjugates for reducing glucose transport into a cell Download PDF

Info

Publication number
US20110243851A1
US20110243851A1 US13/139,170 US200913139170A US2011243851A1 US 20110243851 A1 US20110243851 A1 US 20110243851A1 US 200913139170 A US200913139170 A US 200913139170A US 2011243851 A1 US2011243851 A1 US 2011243851A1
Authority
US
United States
Prior art keywords
glucose
cell
peg
label
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/139,170
Other languages
English (en)
Inventor
Karthikeyan Narayanan
Andrew Chwee Aun Wan
Jackie Y. Ying
Nandanan Erathodiyil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Priority to US13/139,170 priority Critical patent/US20110243851A1/en
Publication of US20110243851A1 publication Critical patent/US20110243851A1/en
Assigned to AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH reassignment AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AUN, ANDREW WAN CHWEE, ERATHODIYIL, NANDANAN, NARAYANAN, KARTHIKEYAN, YING, JACKIE Y.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Definitions

  • the present invention relates to glucose-polyethylene glycol conjugates and the use of such conjugates to reduce glucose transport into a cell.
  • GLUTs glucose transporters
  • 13 GLUTs have been identified to date, and have been categorized into three classes. Class I includes GLUT1 to GLUT4, class II includes GLUT5, GLUT7, GLUT9 and GLUT11, and class III includes GLUT6, GLUT8, GLUT10, GLUT12 and GLUT13.
  • the different transporters have different kinetics and affinities towards glucose and other hexoses.
  • the expression level of the different GLUTS in various tissues varies depending on the metabolic consumption of glucose by the particular tissue type.
  • GLUT1 is a ubiquitously expressed GLUT and GLUT1 and GLUT3 expression levels have been found to be much higher in cancerous cells than in normal cells (1). This overexpression has been observed in a wide variety of different cancer cell types (2-14). Extensive studies with breast cancer patients indicated increased GLUT 1 activity among the patients (15, 16).
  • Metabolic targeted cancer therapy is a relatively new field in cancer therapeutic research and is designed to take advantage of the inherent hyper-metabolic characteristics of cancer cells.
  • Glufosfamide is a small molecule generated by the conjugation of ifosfamide and glucose. This compound enters the cancer cells through the GLUT proteins. It breaks down in the cell, leading to the release of the toxin (ifosfamide) inside the cell (25-28).
  • 2-deoxy-glucose (2-DG) has been shown to be a promising analog.
  • 2-DG is an orally administered glucose analog that inhibits the glycolysis pathway of ATP production in cancer cells.
  • 2-DG accumulates in the cancer cells because the phosphorylated 2-DG cannot be processed by glycolytic enzymes (31, 32).
  • 2-DG can elicit 50% apoptotic cells at a concentration of 4 mM in the SkBr3 (human breast cancer) cell line (33).
  • SkBr3 human breast cancer
  • Noguchi et al. have used anti-sense against GLUT-1 to suppress tumor growth in MKN45 (gastric cancer) cell line. Comparison of tumor development in nude mice demonstrated that the cells expressing anti-sense GLUT-1 develop tumor much more slowly than the wild-type cells (35).
  • the present invention relates to novel glucose-polyethylene glycol (glucose-PEG) conjugates and their use to reduce glucose transport into a cell.
  • glucose-PEG conjugates may be useful to reduce cellular proliferation, particularly in respective of proliferative disorders, such as cancer.
  • the glucose-PEG conjugates of the present invention may also be labelled with a detectable label, and thus may be useful for imaging of hyper-proliferative cells such as cancer cells.
  • the present invention takes advantage of the overexpression of GLUTs in hyper-proliferative cells in order to control cellular proliferation, potentially leading to the death of the hyper-proliferative cells.
  • the glucose-PEG conjugate may be used to target and induce apoptosis in hyper-proliferating cells, such as cancer cells, as a result of reduced glucose transport into the cells. Cancer cells often thrive on glycolytic enzymes that break down glucose into ATP in an anaerobic process. Glucose uptake by the GLUTs has been shown to be high in many cancerous cells and tissues.
  • the glucose-PEG conjugates of the present invention are able to bind to the GLUTs, thus taking advantage of the GLUT overexpression in hyper-proliferative cells such as cancer cells.
  • the glucose-PEG conjugates are not transported into the cells and thus binding of the glucose-PEG conjugates to a GLUT reduces the availability of GLUTs for transporting glucose into the cell, potentially triggering apoptosis.
  • glucose-PEG conjugates of the present invention may be useful to control proliferation of hyper-proliferative cells such as cancer cells, including tumor cells within a tumor core where blood vascularization may be limited. Direct injection into the tumor core may reduce proliferation of the tumor while having minimal effect on surrounding healthy tissue.
  • the invention provides a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety.
  • Conjugation of the PEG moiety to the C1 position of the glucose moiety may occur via an amine linkage.
  • the PEG moiety may comprise a linear, branched, dendritic, hyperbranched, star or comb PEG, and may be terminated at one or both ends with an end group.
  • the glucose-PEG conjugate may further comprise a linker moiety connecting the PEG moiety to the glucose moiety.
  • the glucose-PEG conjugate may also further comprise a detectable label.
  • the detectable label may be a PET label, an SPECT label, an MRI label, a quantum dot label, a coloured label, a fluorescent label, a radiolabel or a label that may be detected by an antibody or antibody fragment.
  • the invention provides a method of reducing glucose transport into a cell comprising contacting the cell with a glucose-PEG conjugate as described herein.
  • the cell may be a hyper-proliferative cell.
  • the invention provides a method of imaging a hyper-proliferative cell comprising contacting a hyper-proliferative cell with a glucose-PEG conjugate as described herein comprising a detectable label; and detecting the detectable label.
  • the detecting may involve fluorescence microscopy, positron emission tomography imaging, single photon emission computed tomography imaging or magnetic resonance imaging.
  • the cell may be an in vitro cell.
  • the cell may be an in vivo cell, including a cell that is associated with a proliferative disorder.
  • contacting may include administering an effective amount of the glucose-PEG conjugate at the site of a hyper-proliferating cell in a subject.
  • the above described methods may further comprise contacting the cell with a chemotherapeutic agent.
  • the invention provides a pharmaceutical composition comprising a glucose-PEG conjugate as described herein.
  • the invention provides use of a glucose-PEG conjugate as described herein, including use in the preparation of a medicament, for reducing glucose transport into a cell.
  • the invention provides use of a glucose-PEG conjugate as described herein, including use in the preparation of a medicament, for treating a proliferative disorder in a subject.
  • the invention provides use of a glucose-PEG conjugate as described herein comprising a detectable label, including use in the preparation of a composition, for imaging a hyper-proliferative cell.
  • FIG. 1 Structure of an exemplary glucose-PEG-BODIPY.
  • the PEG moiety is depicted as only two repeating ethyloxo units. However, the PEG moiety may be larger.
  • FIG. 2 Structure of an exemplary glucose-PEG-OH, synthesized by conjugating glucose with an amino-terminated PEG and then reaction with caprolactone. As with FIG. 1 , the PEG moiety may be larger than depicted.
  • FIG. 3 Structure of an exemplary glucose-branched PEG synthesized by conjugating glucose with an amino-terminated branched PEG and then reaction with caprolactone. Each n is independently greater than or equal to 1.
  • FIG. 4 Synthetic scheme for synthesis of glucose-PEG-BODIPY.
  • FIG. 6 Competition assay. Competition binding assay was performed in the presence of different concentrations of glucose added to the medium containing GPB (200 ⁇ M). The cells were incubated for 30 min at 37° C. The cells were washed with PBS, and the total intensity was measured using a plate reader. The total intensity for the control cells with GPB and without glucose was taken as 100%.
  • FIG. 7 Dose-dependent cell death in MCF-7 cells.
  • MCF-7 cells were seeded onto 96-well plates at least 24 h prior to the experiment. Different concentrations of GPB were added and further cultured for 7 days. The medium was changed everyday along with the specified GPB concentration. MTT assay was performed to assess the cell viability. Control cells received no GPB treatment. Cell viability was normalized with that of the control cells.
  • FIG. 8 Effect of PEG on MCF-7 cells.
  • the MCF-7 cells were treated with 200 ⁇ M and 400 ⁇ M of PEG, and 200 ⁇ M of GPB.
  • the cells were treated as described in FIG. 3 , followed by the MTT assay.
  • FIG. 9 Effect of GPP on MCF-7 cells.
  • the MCF-7 cells were cultured on a 96-well plate. 200 ⁇ M and 400 ⁇ M of GPP were added to the cells, and the cell viability was analyzed after 7 days of culture. The medium was changed everyday with the specified GPP concentration. Value for the control cells without GPP was taken as 100% viable.
  • FIG. 10 Binding of GBP to GLUT1.
  • Human breast cancer cells MCF-7 were incubated with 200 ⁇ M of GPB in the presence of the increasing concentrations of un-modified glucose. After 30 minutes the fluorescence intensity was measured using a plate reader.
  • FIG. 11 Gene expression in lung cancer cells treated with GBrP.
  • Human lung cancer cells H1299 were treated for 3 days with 200 ⁇ M of modified glucose (GBrP).
  • Control cells were prepared without treatment.
  • Total RNA was extracted from the cells and reverse transcribed.
  • a PCR array containing primers to identify the apoptotic pathway was used to identify the apoptosis pathway between control and treated cells in lung cancer cells.
  • FIG. 12 Gene expression in prostate cancer cells treated with GBrP.
  • Human prostrate cancer cells (DU145) were treated for 3 days with 200 ⁇ M of modified glucose (GBrP). Control cells were prepared without treatment. Total RNA was extracted from the cells and reverse transcribed. A PCR array containing primers to identify the apoptotic pathway was used to identify the apoptosis pathway between control and treated cells in prostate cancer cells.
  • Table 1 Effect of GBrP and branched PEG (BrP) was tested on different cancer cell lines along with normal breast epithelial cells (MCF-10A). Cells were treated as described in FIG. 3 with 200 ⁇ M of either BrP or GBrP. MTT assay was carried out to monitor the viability of the cells. Values obtained for the cells without any treatments were kept as 100%.
  • a glucose-PEG conjugate having the PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose.
  • the glucose moiety of the glucose-PEG conjugate is a linear glucose, meaning that the glucose is in an open form and has not cyclised.
  • Cyclic glucose is the form of glucose typically found in biological systems, in which the C1 to C5 carbons, together with an oxygen atom, form a six-membered ring.
  • the glucose-PEG conjugate the glucose is linear, leaving the C1 position available for conjugation to the PEG moiety.
  • the linear glucose is still able to bind to the GLUTs, but the linear form of glucose is not typically found in biological systems, and does not tend to enter glycolytic metabolic pathways.
  • the PEG moiety may be any PEG moiety.
  • polyethylene glycol or poly(ethylene glycol) refers to a polymer made up of monomers of ethylene glycol condensed to form the polymer.
  • the PEG used may be monodispersed, meaning the PEG preparation or solution used to form the conjugate has chains of uniform length, or may be polydispersed, meaning the PEG preparation or solution used has chains of varying length.
  • the PEG moiety of the glucose-PEG conjugate may be of any length, for example from 2 to 500 repeating units, or having an average molecular weight of from about 300 g/mol to about 10,000,000 g/mol.
  • the PEG may be (all average molecular weight) PEG 200, PEG 300, PEG 400, PEG 600, PEG 800, PEG 1000, PEG 1500, PEG 2000, or PEG 3350.
  • the PEG moiety may be a linear PEG.
  • the PEG may be a branched PEG.
  • Branched PEG includes any PEG having one or more branches of PEG groups extending from a PEG backbone, and includes specific arrangements or degrees of branching, such as a hyperbranched PEG, a dendritic PEG, a star PEG, or a comb PEG.
  • the PEG is a branched PEG.
  • the PEG used to form the conjugate may be terminated at one or both ends with an end group, for example an amino group, a hydroxyl group, a methyl ether group, a caprolactone group, a carbohydrate moiety or one or more amino acids.
  • an end group for example an amino group, a hydroxyl group, a methyl ether group, a caprolactone group, a carbohydrate moiety or one or more amino acids.
  • the PEG moiety is conjugated to the linear glucose moiety at the C1 position of the glucose molecule.
  • the C1 position in free linear glucose is part of an aldehyde functional group, that is, in free linear glucose the C1 carbon atom is bonded to an oxy functional group and a hydrogen atom, as well as to the C2 carbon atom.
  • the oxy portion of the aldehyde group may be removed by the conjugation of the PEG moiety, or may be involved in the conjugation reaction and thus may be converted to another functional group, for example the oxy group may become an oxo group, forming an ether linkage to the PEG moiety.
  • the PEG moiety (or an end group on the PEG moiety) may be bonded directly to the C1 carbon or may be bonded to the oxygen of the aldehyde group.
  • the PEG used to form the conjugate has a free primary amino group at least at the terminus that is to be conjugated to the C1 position of the linear glucose, and following conjugation, the oxy group is replaced by a secondary amino group connecting the linear glucose moiety to the PEG moiety via an amine linkage.
  • the PEG moiety including an end group, may be directly attached to the linear glucose moiety at the C1 position, or may be attached via a linker moiety.
  • a linker that is connected to the C1 position of glucose (or via reaction with the aldehyde functionality at the C1 position), may also be attached to the PEG moiety, including an end group on the PEG moiety, thus linking together the glucose moiety and the PEG moiety via an attachment at the C1 carbon, as described above.
  • the glucose-PEG conjugate may include a detectable label.
  • the label may be attached anywhere on the glucose-PEG conjugate, including attached to the PEG moiety, and may be attached for example at the free end of the PEG moiety or (end group) not conjugated to the glucose moiety.
  • the detectable label may be any label that is detectable using known detection methods, including imaging methods.
  • the detectable label may be a PET label, an SPECT label, an MRI label, a quantum dot label, a coloured label, a fluorescent label, a radiolabel or a label that may be detected by an antibody or antibody fragment.
  • fluorescent labels include BODIPY, FITC, Rhodamine, TRITC, Texas Red, cyanine dyes (e.g. Cy3 or Cy5) or Alexa fluors.
  • Radiolabels include moieties or groups having at least one radioactive isotope, and include moieties or groups having a positron emitting radioactive isotope or a gamma emitting radioactive isotope.
  • radiolabels such as PET labels useful for PET scanning may include an unstable positron-emitting isotope.
  • Such isotopes may be synthesized in a cyclotron by bombarding nitrogen, carbon, oxygen, or fluorine with protons.
  • Examples of the isotopes used for PET labels include 15 O (half-life: 2 min), 18 F (half-life: 110 min), and 11 C (half-life: 20 min).
  • Positron or photon emitting atoms such as 18 F, 11 C, 125 I, 123 I, 16 N, 15 O, 3 H, 133 Xe, 111 In, 68 Ga and other isotopes of metals such as technetium, or copper may be used in PET labels or SPECT labels.
  • MRI labels include T1 (Gd) and T2 (Fe 3 O 4 ) contrast agents.
  • the glucose-PEG conjugate comprises the conjugate depicted in FIG. 1 , FIG. 2 or FIG. 3 .
  • the glucose-PEG conjugate is the conjugate depicted in FIG. 1 , FIG. 2 or FIG. 3 .
  • each n is independently 1 or greater, or from 1 to 500.
  • the glucose-PEG conjugate has the arrangement as depicted in FIG. 1 or FIG. 2 , but having the PEG moiety longer than depicted in the relevant Figure, up to 500 repeating ethylene glycol units.
  • the glucose-PEG conjugates may be synthesized using standard known organic synthesis methods. Linear glucose and various PEGs are readily commercially available. Conjugation may be readily performed using known reactions to reaction an appropriate functional group on the terminus of the PEG molecule or on a linker molecule with the free aldehyde located at the C1 position of the linear glucose molecule. Similarly, standard chemical coupling reactions may, be used to attach any detectable label, including attachment to the PEG moiety, either before or after conjugation to the glucose moiety.
  • conjugation of the amino group with the C1 carbon atom may be performed in accordance with Example 1 set out below, and the synthetic scheme described in FIG. 4 .
  • the glucose-PEG conjugate binds to the GLUTs but is not transported into the cell. Without being limited to any particular theory, the glucose-PEG conjugate appears to bind to the GLUTs, blocking binding and transport of glucose, thus reducing the cell's internal glucose supply available for glycolysis, and thus reducing the proliferation rate of the cell.
  • the cell surface of the normal cells contains glucose transporters along with transporters for other saccharides such as fructose and galactose.
  • glucose transporters are the primary transporters and the cancer cells depend on the glucose intake for their ATP generation and oxygen production under anaerobic conditions. Blocking the glucose receptors in hyper-proliferating cancer cells may lead to cell death, as was found in studies involving siRNA and antibody based blockage of the glucose receptors leading to cell death in proliferating cancer cells.
  • the PEG portion of the conjugate is highly soluble, and is generally biologically inert, biodegradable, non-toxic and non-immunogenic.
  • the glucose-PEG conjugated described herein is useful for reducing glucose uptake by a cell, including in in vivo contexts.
  • a method of reducing glucose transport into a cell comprising contacting the cell with a glucose-PEG conjugate as described herein. Contacting the cell with the conjugate thus allows the conjugate to bind to the GLUTs on the surface of the hyper-proliferative cell.
  • Glucose transport into a cell refers to the process of moving glucose from the exterior of a cell into the interior of the cell, including that mediated by GLUTs.
  • Reducing glucose transport in a cell refers to lessening the amount of glucose that is taken up into the cell, including via transport by GLUTs. Reducing includes lessening as well as completely blocking glucose transport, including glucose transport by GLUTs. Reducing may lead to slowing of proliferation by the cell so that the cell still proliferates but not as quickly as in the absence of the glucose-PEG conjugate, or may lead to cessation of proliferation, or even cell death, including apoptotic cell death.
  • cell refers to and includes a single cell, a plurality of cells or a population of cells where context permits, unless otherwise specified. Similarly, reference to cells also includes reference to a single cell where context permits, unless otherwise specified.
  • the cell may be any cell, including an in vitro cell, a cell in culture, an in vivo cell, or an ex vivo cell explanted from a subject.
  • the cell may be derived from any organism that expresses GLUTs and that undergoes anaerobic glycolysis, for example an animal, including a mammal, including a human.
  • the cell may be a primary cell or it may be a cell from an established cell line, including a cancer cell line.
  • the cell may be a hyper-proliferative cell.
  • a hyper-proliferative cell or hyper-proliferating cell is a cell in which proliferation is uncontrolled or is increased relative to a healthy cell.
  • a healthy cell is a cell of the same cell type but that is not hyper-proliferating or in which proliferation is under normal cellular controls.
  • the hyper-proliferative cell may be a cell associated with a proliferative disorder, including a cell within a solid tumor, and may be a cell that is being treating with a further cancer therapy.
  • a cell is associated with a proliferative disorder if that cell is a cell that is abnormally proliferating so as to result in the disorder in a subject in which the cell is located, or if the disorder is characterized by the proliferation of such a cell.
  • a proliferative disorder is a disease or disorder in which a cell of a subject is abnormally proliferating, resulting in uncontrolled growth and division of the cell, which in a healthy individual would not be proliferating or would be proliferating in a controlled manner.
  • the proliferative disorder may be characterized by the proliferation of malignant or non-malignant cell populations, including in a solid tumor.
  • Such disorders include cancer including breast cancer, liver cancer, gastric cancer, bladder cancer, colon cancer, prostate cancer, lung cancer, nasopharyngeal carcinoma, cervical carcinoma, skin cancer.
  • contacting the cell with the glucose-PEG conjugate may comprise adding the conjugate to the buffer solution or growth medium in which the cell is contained.
  • the glucose-PEG conjugate may be added to the buffer solution or growth medium at a concentration of about 0.01 mM or greater, about 0.02 mM or greater, about 0.05 mM or greater or about 1.0 mM or greater.
  • the glucose-PEG conjugate may be added to the buffer solution or growth medium at a concentration of from about 0.01 mM to about 20 mM, about 0.02 to about 10 mM, or about 0.02 to about 0.5 mM.
  • the glucose-PEG conjugate may comprise a detectable label as described above, in order to allow for confirmation that the conjugate is binding to the GLUTs on the exterior surface of the cell by detecting the location of the conjugate after contacting with a cell.
  • the method in certain embodiments may comprise detecting the glucose-PEG conjugate after contacting with the cell.
  • the detecting may include imaging of the cell, including using known fluorescent imaging techniques in vitro.
  • contacting the cell with the glucose-PEG conjugate may comprise administering an effective amount of the conjugate to a subject.
  • an effective amount means an amount effective, at dosages and for periods of time necessary to achieve the desired result, for example, to reduce glucose transport in the cell or to treat the specific proliferative disorder.
  • the method may include treatment of a proliferative disorder in a subject.
  • treating refers to an approach for obtaining beneficial or desired results, including clinical results.
  • beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilization of the state of disease, prevention of development of disease, prevention of spread of disease, delay or slowing of disease progression, delay or slowing of disease onset, amelioration or palliation of the disease state, and remission (whether partial or total).
  • “Treating” can also mean prolonging survival of a patient beyond that expected in the absence of treatment. “Treating” can also mean inhibiting the progression of disease, slowing the progression of disease temporarily, although more preferably, it involves halting the progression of disease permanently.
  • the subject is any animal in need of treatment of a proliferative disorder, including a mammal, including a human.
  • the conjugate may be administered to the subject using standard techniques known in the art.
  • the conjugate may be administered systemically, or may be administered directly at the site at which the proliferating cell that is associated with the proliferative disorder is located. Delivery to the site includes topical administration, injection or surgical implantation, including at a site of a tumor. Delivery may be performed using a drug delivery device, to allow sustained delivery of the conjugate according to a desired release profile. Drug delivery devices including transdermal systems as well as devices for implantation.
  • the concentration and amount of the conjugate to be administered will vary, depending on the proliferative disorder to be treated, the type of cell associated with the proliferative disorder, the type of conjugate that is administered, the mode of administration, and the age and health of the subject.
  • the method also involves imaging of hyper-proliferative cells in vivo.
  • the conjugate may comprise a detectable label, including a fluorescent marker, an MRI label, a PET label, a SPECT label, a radiolabel or a quantum dot, suitable for detection using in vivo imaging techniques.
  • the conjugate can influence the growth of hyper-proliferative cells, the conjugate may be used in combination with other cancer treatments, including to target drug-resistant cancer cells to make such cells more susceptible to treatment by cancer treatments such as with chemotherapeutic agents.
  • the reducing and/or treating may be further accomplished in combination with a chemotherapeutic agent.
  • a chemotherapeutic agent means that the reducing and/or treating occurs in a time period during which a chemotherapeutic agent is contacted with or administered to the cell.
  • the reducing of glucose transport and the contacting with or administration of the chemotherapeutic agent may occur simultaneously or sequentially, and the respective time period for each may be conterminous or may be overlapping provided that the benefit or effect of the chemotherapy treatment is ongoing in the cell concomitantly with the reducing.
  • the reducing and the administration each may be achieved in one or more discrete treatments or may be performed continuously for a given time period required in order to achieve the desired result.
  • the cell may be further contacted with the chemotherapeutic agent in a manner similar to that described above for contacting with the conjugate, depending on the nature of the chemotherapeutic agent.
  • the cell may be contacted with the chemotherapeutic agent prior to, following, or simultaneously with the conjugate.
  • the chemotherapeutic agent may be a compound that is typically administered to a cell and which has a cytotoxic or cytostatic effect.
  • the chemotherapeutic agent may be an agent that induces apoptosis, such as p53-dependent apoptosis, or that induces cell cycle arrest, including p53-dependent cell cycle arrest, in a cell that is abnormally proliferating, even in the absence of the conjugate.
  • the chemotherapeutic agent may also be an agent that activates p53 or p21 in an abnormally proliferating cell but that does not induce apoptosis in the cell, due to a property of the abnormally proliferating cell, for example an alteration or mutation in p53 or in the p53 pathways.
  • Treatment of the cell with the chemotherapeutic agent in combination with the conjugate induces cell death, or increases sensitivity to cell death, at a level greater than that which is observed in the absence of the conjugate.
  • the chemotherapeutic agent may be a DNA damaging agent or a genotoxic agent that can activate p53-dependent apoptosis or p53-dependent cell cycle arrest in a proliferating cell.
  • the chemotherapeutic agent may be, without limitation, a small molecule, a peptide or a protein, an anthracycline, an alkylating agent, an alkyl sulfonate, an aziridine, an ethylenimine, a methylmelamine, a nitrogen mustard, a nitrosourea, an antibiotic, an antimetabolite, a folic acid analogue, a purine analogue, a pyrimidine analogue, an enzyme, a podophyllotoxin, a platinum-containing agent or a cytokine.
  • the chemotherapeutic agent may be chosen as a chemotherapeutic agent that is known to be effective against the particular cellular proliferative disorder and cell type.
  • the chemotherapeutic agent is cisplatin, paclitaxel, Adriamycin (ADR), 5-fluorouracil (5-FU), etoposide, or camptothecin or a derivative or analog thereof.
  • glucose-PEG conjugate including use of the conjugate for reducing glucose transport into a cell, or for treating a proliferative disorder in a subject.
  • the use may include use in the manufacture of a medicament or pharmaceutical composition.
  • the glucose-PEG conjugate may be formulated as an ingredient in a pharmaceutical composition. Therefore, in a further embodiment, there is provided a pharmaceutical composition comprising a glucose-PEG conjugate, and may further include a pharmaceutically acceptable diluent.
  • the invention in one aspect therefore also includes such pharmaceutical compositions for use in reducing glucose transport in a cell and/or for use in treating a proliferative disorder.
  • the pharmaceutical compositions may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives and various compatible carriers.
  • the glucose-PEG conjugate may be formulated in a physiological salt solution.
  • the pharmaceutical composition can be prepared by known methods for the preparation of pharmaceutically acceptable compositions suitable for administration to patients, such that an appropriate quantity of the glucose-PEG conjugate, and any additional active substance or substances, is combined in a mixture with a pharmaceutically acceptable vehicle.
  • Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985).
  • the pharmaceutical compositions include, albeit not exclusively, solutions of the glucose-PEG conjugate, in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffer solutions with a suitable pH and iso-osmotic with physiological fluids. A person skilled in the art would know how to prepare suitable formulations.
  • the proportion and identity of the pharmaceutically acceptable diluent is determined by chosen route of administration, compatibility with live cells, and standard pharmaceutical practice. Generally, the pharmaceutical composition will be formulated with components that will not significantly impair the properties of the glucose-PEG conjugate to reduce glucose transport into a cell.
  • compositions may additionally contain other therapeutic agents useful for treating the particular proliferative disorder, for example a cytotoxic agent, for example a chemotherapeutic agent.
  • a cytotoxic agent for example a chemotherapeutic agent.
  • the pharmaceutical composition may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art.
  • the composition is administered topically, surgically or by injection (subcutaneously, intravenously, intramuscularly, etc.) directly at the desired site where the cells that are proliferating in an uncontrolled manner are located in the patient, including at or within a tumor.
  • the dose of the pharmaceutical composition that is to be used depends on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and other similar factors that are within the knowledge and expertise of the health practitioner. These factors are known to those of skill in the art and can be addressed with minimal routine experimentation.
  • a method of imaging a hyper-proliferative cell including both in vitro and in vivo.
  • the method of imaging includes contacting a cell with a glucose-PEG conjugate as described herein, the conjugate comprising a detectable label; and detecting the detectable label in order to image the hyper-proliferative cell.
  • the detectable label is any label that is detectable using standard detection methods, including imaging methods.
  • In vitro imaging methods include fluorescence microscopy techniques.
  • Imaging methods for in vivo imaging include magnetic resonance imaging (MRI) including functional magnetic resonance imaging (fMRI) techniques, positron emission tomography (PET) imaging techniques, and single photon emission computed tomography (SPECT) imaging techniques.
  • MRI magnetic resonance imaging
  • fMRI functional magnetic resonance imaging
  • PET positron emission tomography
  • SPECT single photon emission computed tomography
  • the glucose-PEG conjugate is contacted with the hyper-proliferative cell in a manner as described above to allow the conjugate to bind to the GLUTs on the surface of the hyper-proliferative cell.
  • the glucose-PEG conjugate may be added to a buffer or culture medium containing the cell.
  • the glucose-PEG conjugate may be administered to a subject in which a hyper-proliferative cell is desired to be imaged, as described above, including by topical administration, injection or surgical implantation, including at a site of a tumor.
  • inclusion of the conjugate in a composition may aid in administration of the conjugate to a subject.
  • the hyper-proliferative cell may be incubated with the glucose-PEG conjugate prior to detecting.
  • the incubation may be for any period of time so as to allow for the conjugate to bind to the GLUTs on the hyper-proliferative cell, for example for 5 minutes or longer, for 15 minutes or longer, for 30 minutes or longer or for 1 hour or longer.
  • the method comprises detecting the detectable label.
  • the method of detecting will depend on the detectable label used.
  • Standard detection methods may be used to detect the detectable label, including the above-mentioned fluorescence microscopy techniques, MRI techniques, PET imaging techniques, and SPECT imaging techniques. Such methods are known to a skilled person and may be performed in accordance with standard, known methods.
  • the imaging method may be used in vitro to identify a hyper-proliferative cell within a population of cells, or to identify conditions that induce hyper-proliferation within a population of cells.
  • the imaging method is also useful for in vivo imaging, and may be used to identify a hyper-proliferative cell within a subject, including within a solid tumor, or may be used to monitor treatment progression within a subject.
  • glucose modified with poly(ethylene glycol) (PEG) reduces cell proliferation and induces apoptosis in human breast cancer cell line, MCF-7.
  • Glucose-PEG-BODIPY (GPB): Glucose was modified with PEG-conjugated to BODIPY. BODIPY was used as a red fluorescent indicator for cell imaging.
  • a flame dried reaction vial (2 mL) was charged with a solution of glucose-PEG-NH 2 (32 mg, 0.1 mmol) and BODIPY 650/665-X (64 mg, 0.1 mmol) under argon, and the mixture was cooled in an ice bath at 0° C. Dry dimethylformamide (DMF; Aldrich, 1 mL) was added dropwise and was stirred at 0° C. for 2 h under argon.
  • DMF dimethylformamide
  • the reaction mixture was then brought to room temperature, and continuously stirred for 24 h under argon in the dark.
  • the reaction was monitored by reverse-phase high-pressure liquid chromatography (HPLC; Waters Corporation, USA).
  • HPLC reverse-phase high-pressure liquid chromatography
  • DMF was removed under reduced pressure and the blue residue was purified by reverse-phase flash column chromatography using a Combiflash separating system (ISCO Combiflash Companion, USA).
  • the desired fractions were collected and lyophilized to obtain the FR-BODIPY-glucose as a bluish green solid (75 mg, 90%).
  • the final conjugated product was purified by exhaustive filtration through an Amicon membrane filter (polyethersulfone (PES) membrane, 10 kDa molecular weight cutoff), and lyophilized to obtain a product as a colorless sticky solid.
  • Amicon membrane filter polyethersulfone (PES) membrane, 10 kDa molecular weight cutoff
  • lyophilized to obtain a product as a colorless sticky solid.
  • a representative structure of glucose-branched PEG is shown in FIG. 3 .
  • MCF-7 breast epithelial cell line
  • H1299 lung cancer
  • HepG2 liver cancer
  • DU145 prostate cancer
  • Caco2 colon cancer
  • AGS gastric cancer
  • MCF-10A normal breast epithelial cell line
  • the cells were maintained in the growth medium as described by ATCC. Approximately 10,000 cells were seeded onto a 96-well plate. Modified glucose compounds were added to the cells after 24 h of seeding. The cells were further cultured in the presence of the modified glucose compounds for up to 7 days. The medium was changed everyday along with the specified concentration of modified glucose. At the end of the treatment, the cells were assayed for viability using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.
  • MCT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
  • MTT assay was performed using the TACSTM MTT cell proliferation assay kit (Trevigen Inc, MD, USA). Briefly, after treatment of cells, 10 ⁇ l of MTT reagent was added and incubated at 37° C. for 4 h. The cells were lysed using detergent for 4 h at room temperature. The absorbance was measured in a standard plate reader at 570 nm.
  • Competition assay was performed to demonstrate the specificity of the GPB binding to the GLUTs. GPB binding to the cell surface could be quantified by measuring the fluorescence intensity. Addition of unlabeled glucose at different concentrations (10 mM, 20 mM, 30 mM, 35 mM and 40 mM) to the media competed with the GPB binding, leading to the differences in the fluorescence intensity. Cells were incubated with GPB and various concentrations of glucose for 30 min at 37° C. The medium was removed and the cells were washed briefly with PBS twice. The fluorescence intensity was measured with an excitation of 488 nm and an emission of 522 nm. The fluorescence intensity was normalized by that of the control cells.
  • the MCF-7 cells were seeded on a 6-well plate at least 24 h prior to imaging. The cells were incubated with GPB (200 ⁇ M) for 1 h. The cells were washed with PBS (without calcium and magnesium) thrice. Live imaging was performed with fluorescence microscopy. Metamorph (Molecular Devices, USA) and Image J (freeware from NIH, USA) were used for image capturing and processing.
  • a fluorescent tag (BODIPY) was conjugated onto glucose via PEG.
  • This GPB was used in the initial imaging studies. Fluorescence imaging of MCF-7 cells fed with GPB clearly indicated that the GPB molecules were localized on the plasma membrane of the cells ( FIG. 5 ). The binding of the modified GPB was challenged with different concentrations of glucose. The competition binding assay suggested that glucose competed with the GPB in binding to the GLUTs ( FIG. 6 ).
  • the cell viability assay was performed on cells treated with different GPB concentrations. There was a gradual dose-dependent decrease in the cell viability with increasing GPB concentration ( FIG. 7 ). ⁇ 63% reduction in cell viability was observed when the cells were treated with 200 ⁇ M of GPB ( FIG. 8 ). PEG alone at concentrations of 200 ⁇ M and 400 ⁇ M did not have any effect on the MCF-7 cells ( FIG. 8 ). However, cells treated with 200 ⁇ M of GPB showed a drastic reduction in cell viability ( ⁇ 70%) ( FIG. 8 ).
  • a new compound was also synthesized to replace the BODIPY in GPB with another PEG molecule.
  • This new compound has two PEGs conjugated to the glucose (glucose-PEG-PEG or GPP).
  • the cell viability was reduced to 57% and 42% at 200 ⁇ M and 400 ⁇ M of GPP, respectively ( FIG. 9 ). In contrast, the cell viability was not affected by 400 ⁇ M of PEG-PEG.
  • a further strategy to increase the levels of cell death was to further modify the glucose with a branched structure.
  • Glucose was coupled to a branched PEG (4-arm PEG or BrP) as described in the methods.
  • the resulting compound was designated as glucose-conjugated branched PEG or GBrP.
  • 200 ⁇ M of GBrP could reduce the viability of MCF-7 breast cancer cells by >90%, where as 200 ⁇ M of branched PEG only decreased the viability of the same cell line by 7% (see Table 1).
  • Table 1 also shows that 200 ⁇ M of GBrP reduced the viability of normal breast cells by only 29%. This illustrates the ability of GBrP to preferentially target cancer cells.
  • GBrP was also demonstrated to significantly inhibit the viability of various different cancer cell lines (see Table 1).
  • a glucose competition assay was carried out to confirm that the modified glucose-PEG is binding to the GLUT1 receptors. Increasing concentrations of un-modified glucose were used. The human breast cancer cells (MCF-7) were incubated with 200 ⁇ M of GPB in the presence of the increasing concentrations of un-modified glucose. After 30 minutes the fluorescence intensity was measured using a plate reader. As indicated in FIG. 10 , the intensity of the fluorescence decreases with the increase in un-modified glucose, indicating that the un-modified glucose is competing for the GLUT1 receptor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
US13/139,170 2008-12-11 2009-12-11 Glucose-peg conjugates for reducing glucose transport into a cell Abandoned US20110243851A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/139,170 US20110243851A1 (en) 2008-12-11 2009-12-11 Glucose-peg conjugates for reducing glucose transport into a cell

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19364008P 2008-12-11 2008-12-11
PCT/SG2009/000477 WO2010068183A1 (en) 2008-12-11 2009-12-11 Glucose-peg conjugates for reducing glucose transport into a cell
US13/139,170 US20110243851A1 (en) 2008-12-11 2009-12-11 Glucose-peg conjugates for reducing glucose transport into a cell

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/SG2009/000477 A-371-Of-International WO2010068183A1 (en) 2008-12-11 2009-12-11 Glucose-peg conjugates for reducing glucose transport into a cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/149,493 Division US9051418B2 (en) 2008-12-11 2014-01-07 Glucose-PEG conjugates for reducing glucose transport into a cell

Publications (1)

Publication Number Publication Date
US20110243851A1 true US20110243851A1 (en) 2011-10-06

Family

ID=42242962

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/139,170 Abandoned US20110243851A1 (en) 2008-12-11 2009-12-11 Glucose-peg conjugates for reducing glucose transport into a cell
US14/149,493 Expired - Fee Related US9051418B2 (en) 2008-12-11 2014-01-07 Glucose-PEG conjugates for reducing glucose transport into a cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/149,493 Expired - Fee Related US9051418B2 (en) 2008-12-11 2014-01-07 Glucose-PEG conjugates for reducing glucose transport into a cell

Country Status (4)

Country Link
US (2) US20110243851A1 (de)
EP (1) EP2370399A4 (de)
SG (1) SG171985A1 (de)
WO (1) WO2010068183A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130034597A1 (en) * 2011-02-04 2013-02-07 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof
US9051418B2 (en) 2008-12-11 2015-06-09 Agency For Science, Technology And Research Glucose-PEG conjugates for reducing glucose transport into a cell
US9783690B2 (en) 2012-05-09 2017-10-10 Oce-Technologies B.V. Ink composition, a method for preparing the ink composition and use thereof, a water soluble resin and use thereof in an ink composition

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470627B (zh) * 2012-07-19 2018-05-11 陶氏环球技术有限责任公司 复合聚酰胺膜
CN106755435B (zh) * 2016-12-29 2020-10-02 王晖 检测糖酵解相关基因的产品在制备鼻咽癌诊断试剂盒中的应用
CN107058486B (zh) * 2016-12-29 2020-10-02 王晖 检测鼻咽癌糖酵解相关基因分型的引物组及试剂盒
SG11202109702QA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicles for vaccine delivery
US20220387906A1 (en) 2019-03-21 2022-12-08 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
CA3193107A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014666A1 (en) * 2002-05-14 2006-01-19 Shishan Ji Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3268898D1 (en) 1981-11-28 1986-03-13 British Petroleum Co Plc Compounds and compositions for oil recovery
WO1999011692A1 (en) 1997-09-03 1999-03-11 The Regents Of The University Of California Novel biomimetic hydrogel materials
US6534038B2 (en) 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
AU1609702A (en) 2000-12-21 2002-07-01 Aventis Pharma Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
PL191556B1 (pl) 2001-04-27 2006-06-30 Politechnika Wroclawska Sposób wytwarzania niejonowych surfaktantów cukrowych
PL191555B1 (pl) 2001-04-27 2006-06-30 Politechnika Wroclawska Niejonowe pochodne bisalkanoilobisglukamin
KR100811969B1 (ko) 2004-02-18 2008-03-10 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 당쇄 리간드 복합체, 및 그 리간드 복합체를 이용한단백질의 분석 방법
JP2008528621A (ja) * 2005-01-27 2008-07-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 腎細胞ガンを処置するための方法
SG171985A1 (en) 2008-12-11 2011-07-28 Agency For Science Techonology And Res Glucose-peg conjugates for reducing glucose transport into a cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014666A1 (en) * 2002-05-14 2006-01-19 Shishan Ji Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9051418B2 (en) 2008-12-11 2015-06-09 Agency For Science, Technology And Research Glucose-PEG conjugates for reducing glucose transport into a cell
US20130034597A1 (en) * 2011-02-04 2013-02-07 Aegis Therapeutics Llc Orally bioavailable peptide drug compositions and methods thereof
US9783690B2 (en) 2012-05-09 2017-10-10 Oce-Technologies B.V. Ink composition, a method for preparing the ink composition and use thereof, a water soluble resin and use thereof in an ink composition
EP2847286B1 (de) * 2012-05-09 2019-08-07 OCE-Technologies B.V. Tintenzusammensetzung, verfahren zur herstellung der tintenzusammensetzung, und verwendung davon, ein wasserlösliches harz und verwendung davon in einer tintenzusammensetzung

Also Published As

Publication number Publication date
US20140193849A1 (en) 2014-07-10
EP2370399A1 (de) 2011-10-05
EP2370399A4 (de) 2013-05-22
WO2010068183A1 (en) 2010-06-17
US9051418B2 (en) 2015-06-09
SG171985A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
US9051418B2 (en) Glucose-PEG conjugates for reducing glucose transport into a cell
Al Faraj et al. Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model
Song et al. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer
EP3247375B1 (de) Antiseneszenzverbindungen und verwendungen davon
Tanasova et al. Targeting sugar uptake and metabolism for cancer identification and therapy: an overview
US9636329B2 (en) Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
US20090092553A1 (en) Monocarboxylate transporters expressed in cancer cells
Liu et al. 3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells
Popova et al. Biotin-decorated anti-cancer nucleotide theranostic conjugate of human serum albumin: Where the seed meets the soil?
Carter et al. Role of human nucleoside transporters in pancreatic cancer and chemoresistance
AU2015209095A1 (en) Novel methods for treating cancer
Dai et al. AMP-guided tumour-specific nanoparticle delivery via adenosine A1 receptor
Javle et al. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil
CN116637122B (zh) 环状RNA circ-DCUN1D4在肝癌诊断和治疗中的新用途
Li et al. Plumbagin-loaded ZIF-90 nanoparticles suppress gastric cancer progression by targeting the YAP1 signaling
Cai et al. Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer
Narayanan et al. Targeting Warburg effect in cancers with PEGylated glucose
Liu et al. CD71/CD44 dual-aptamer-gemcitabine conjugate for tumor co-targeting treatment of bladder cancer
CN108250276B (zh) Cu-64标记的Hsp90抑制剂胰腺癌诊疗一体化分子探针的制备方法
EP2825198B1 (de) Glut-1 zielgerichtete und mit Kurkumin beladene Mizellen
Wang et al. Influences of galactose ligand on the uptake of TADF liposomes by HepG2 cells
US11795197B2 (en) Peptide compositions for immuno-oncology molecular imaging and targeted drug delivery
US20140219925A1 (en) Polymer particles or nano-vectors and use thereof as a drug and/or diagnostic agent
WO2005097142A1 (en) Biologically active compounds with anti-angiogenic properties
Elamin et al. Involvement of mitophagy-mediated cell death in colon cancer cells by folate-appended methyl-β-cyclodextrin

Legal Events

Date Code Title Description
AS Assignment

Owner name: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, SINGA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NARAYANAN, KARTHIKEYAN;AUN, ANDREW WAN CHWEE;YING, JACKIE Y.;AND OTHERS;REEL/FRAME:027112/0338

Effective date: 20110714

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION